ClinicalTrials.gg
RecruitingNCT07484204Updated Sep 16, 2026

Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia

A Phase 1 interventional study of AX251 LAI 45 mg and AX251 LAI 90 mg in Schizophrenia, sponsored by Anxo Pharmaceutical Co., Ltd.. Recruiting at 4 sites in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Anxo Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in Schizophrenia with a site in India — 13 open to participants now, 14 under way, 2 of them phase 3. Schizophrenia · India.

Planned enrollment
65th of 76
48 · median 201
Started
2026
with 6 others
Phase 1
4 of 78
1 open now
Primary completion
2028-07
later than 11 of 13 live
Registered
76th of 78
by date

Among the 78 studies in Schizophrenia with a site in India, this one is the 65th largest by planned enrollment of the 76 interventional ones that give a count, is one of 7 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 11 of the 13 other live ones, and was the 76th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

13 of the 78 studies in Schizophrenia with a site in India are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Schizophrenia with a site in India, or all of them as a file.
02

Study summary

The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of AX251 long-acting injectable (LAI) administered as a single dose in patients with schizophrenia. The study will include sequential dose-escalation cohorts to evaluate different dose levels of AX251 LAI.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • AX251
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 18 to 65 years (inclusive).
  • clinical diagnosis of schizophrenia per the , Fifth Edition, Text Revision (DSM-5-TR) (or later) criteria, at screening.
  • (BMI) 18.5-35.0 kg/m² at screening.
  • Clinical Global Impression-Severity (CGI-S) score ≤4 at screening.
  • Positive and Negative Syndrome Scale (PANSS) total score ≤75 at screening.
  • Clinically stable schizophrenia on current antipsychotic medication other than cariprazine for at least 3 months prior to screening.
  • Subjects must not be taking more than two antipsychotic medications.
  • Able to remain at the study site for 7 days following AX251 LAI injection.
  • Judged by the investigator to be physically and mentally able to participate in the study based on clinical evaluation, physical examination, (ECG), and laboratory assessments.
  • Willing and able to comply with study procedures.
  • Agrees to use protocol-defined during the study.
  • Previous tolerability to oral cariprazine (1.5-6 mg) or willingness to undergo a short oral tolerability test (2-7 days) followed by before study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of psychiatric disorders other than schizophrenia according to (e.g., schizoaffective disorder, major depressive disorder, bipolar disorder, generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, dementia, mild neurocognitive disorder, or personality disorders), except caffeine- or tobacco-related disorders.
  • Substance use disorder (including alcohol or benzodiazepines) within 180 days prior to screening, excluding caffeine and tobacco.
  • History of neuroleptic malignant syndrome, seizure disorder, or tardive dyskinesia, akathisia, or extrapyramidal symptoms.
  • Clinically significant cardiovascular, hematologic, metabolic, hepatic, renal, immunologic, or neurological disease that may interfere with study participation.
  • Severe hepatic impairment ( Class C) at screening.
  • Uncontrolled hypertension.
  • Clinically significant abnormalities at screening.
  • Severe renal impairment (estimated \<30 mL/min).
  • History of syncope or significant orthostatic hypotension at screening.
  • Failure to complete required (≥5 half-lives) for prohibited medications before administration of AX251 LAI.
  • Current treatment with other antipsychotic long-acting injectable (LAI) therapies.
  • Electroconvulsive therapy within 60 days prior to screening.
  • Acute psychosis posing imminent risk to self or others.
  • Acute relapse of schizophrenia at screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    AX251 LAI 45 mg

    AX251 LAI 45mg

    Drug: AX251 LAI 45 mg

  • Experimental
    AX251 LAI 90mg

    AX251 LAI 90mg

    Drug: AX251 LAI 90 mg

  • Experimental
    AX251 LAI 135mg

    AX251 LAI 135mg

    Drug: AX251 LAI 135 mg

  • Experimental
    AX251 LAI 180mg

    AX251 LAI 180mg

    Drug: AX251 LAI 180 mg

Interventions

  • DrugAX251 LAI 45 mg

    Cariprazine 45 mg

  • DrugAX251 LAI 90 mg

    Cariprazine 90 mg

  • DrugAX251 LAI 135 mg

    Cariprazine 135 mg

  • DrugAX251 LAI 180 mg

    Cariprazine 180 mg

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Parameter

    Maximum observed serum concentration of cariprazine and its metabolites desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR) following a single dose of AX251 long-acting injectable (LAI).

    Time frame: Day 1 pre-dose and 1, 2, 3, 4, 8, 12, and 24 hours post-dose. Days 3, 5, 7, 14, 21, 28, 42, 56, and 70

Secondary outcomes

  1. Safety: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number and proportion of participants experiencing treatment-emergent adverse events and serious adverse events during the study.

    Time frame: Baseline to Day 70

07

Study locations

4 of 4 sites recruiting
  • DHS Multispeciality Hospital
    Ahmedabad, India
    Recruiting
  • Health Hospital
    Ahmedabad, India
    Recruiting
  • Divine Multispeciality Hospital
    Gandhinagar, India
    Recruiting
  • Ratandeep Multispeciality Hospital
    Nagar, India
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2028, 22 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 22 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 20, 2026
StartActual
Sep 14, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07484204
Lead sponsor
Anxo Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Sep 14, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Sep 16, 2026

Study contacts

Mico Hsu
Contact
mico_hsu@anxo.com.tw
886-5716223

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion